Please assess the completion status of the following clinical trial:

Trial Title: Trial Comparing Cetuximab With Pemetrexed/Cetuximab Therapy for Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of locally advanced or metastatic (Stage III or IV at entry) non-small cell lung cancer (NSCLC) that is not amenable to curative therapy.~* ECOG performance status 0-2~* Patients must have been previously treated with one platinum-containing or taxane-containing chemotherapy regimen for locally advanced or metastatic disease. Patients are also eligible if they have received one platinum-based chemotherapy regimen as neoadjuvant or adjuvant chemotherapy, but must have received an additional chemotherapy regimen upon recurrence.~* No more than two prior systemic anti-cancer therapies will be allowed.~* Prior radiation therapy is allowed to \<25% of the bone marrow. Prior radiation to the whole pelvis is not allowed, Prior radiotherapy must be completed at least 2 weeks before study enrollment, and the patient must have recovered from the acute toxic effects of the treatment prior to study enrollment.~* Patients must have signed an approved informed consent.~* Male and female patients with reproductive potential must use an approved contraceptive method if appropriate (eg, intrauterine device, birth control pills, or barrier device) during and for 3 months after the study. Female patients must either not be of child bearing potential or have a negative pregnancy test within 7 days of treatment. Patients are considered not of child bearing potential if they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal.~* Age\>18~* Measurable disease in accord with RECIST criteria~* Bone marrow Function: absolute neutrophil count (ANC)\>/=1,500/ul, platelets \>/=l00,000, hemoglobin\> 9g/dL~* Renal function: creatinine clearance (calculated by Cockcroft and Gault method) \>/= 45mL/min~* Hepatic function: bilirubin \</=1.5 x ULN; ALT/AST ,/= 2.5 x ULN; Albumin \>/=2.5 g/dL~Exclusion Criteria:~* Prior treatment with pemetrexed~* Prior therapy that targets the EGF pathway.~* Active or uncontrolled infection.~* Significant history of uncontrolled cardiac disease; i.e., uncontrolled hypertension, unstable angina, and congestive heart failure.~* Pleural or pericardial effusions that cannot be completely evacuated prior to pemetrexed therapy.~* Acute hepatitis or known HIV.~* Prior severe infusion reaction to a monoclonal antibody.~* Any concurrent chemotherapy not indicated in the study protocol or any other investigational agent(s).~* Pregnancy or Breast-feeding.~* Second primary malignancy that is clinically detectable at the time of consideration for study enrollment.~* Inability to interrupt aspirin, or other nonsteroidal anti-inflammatory agents for a 5-day period.~* Inability or unwillingness to take folic acid or vitamin B12 supplementation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cetuximab (Type: ACTIVE_COMPARATOR): Cetuximab initial dosage of 400 mg/m2 over 120 minutes, followed by weekly infusions at 250 mg/m2 over 60 minutes.
- Cetuximab and Pemetrexed (Type: EXPERIMENTAL): Cetuximab initial dosage of 400 mg/m2 over 120 minutes, followed by weekly infusions at 250 mg/m2 over 60 minutes. Starting on day 15 and then subsequently on day 1 of each 21 day cycle, Pemetrexed 500 mg/m2.

Based on this trial design, predict the completion outcome and termination type (if applicable).